1
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
Condition(s):Metastatic Castration-resistent Prostate CancerLast Updated:March 24, 2023Active, not recruiting